The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
第一作者:
R T,Reilly
第一单位:
Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA.
作者:
主题词
3T3细胞(3T3 Cells);动物(Animals);B-淋巴细胞(B-Lymphocytes);女(雌)性(Female);免疫耐受(Immune Tolerance);免疫球蛋白G(Immunoglobulin G);免疫疗法, 过继(Immunotherapy, Adoptive);淋巴细胞活化(Lymphocyte Activation);乳房肿瘤, 实验性(Mammary Neoplasms, Experimental);小鼠(Mice);小鼠, 近交BALB C(Mice, Inbred BALB C);小鼠, SCID(Mice, SCID);肿瘤移植(Neoplasm Transplantation);T淋巴细胞亚群(T-Lymphocyte Subsets);T淋巴细胞(T-Lymphocytes);接种(Vaccination)
PMID
11221874
发布时间
2020-12-22
- 浏览8

Cancer research
880-3页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文